Evaluating prediction of short-term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population-based study.

Journal: Diabetes, obesity & metabolism
Published Date:

Abstract

AIMS: A precision medicine approach in type 2 diabetes (T2D) needs to consider potential treatment risks alongside established benefits for glycaemic and cardiometabolic outcomes. Considering five major T2D drug classes, we aimed to describe variation in short-term discontinuation (a proxy of overall tolerability) by drug and patient routine clinical features and determine whether combining features in a model to predict drug class-specific tolerability has clinical utility.

Authors

  • Pedro Cardoso
    Department of Gastroenterology, São João University Hospital, Alameda Professor Hernâni Monteiro, 4200-427 Porto, Portugal.
  • Katie G Young
    Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK.
  • Rhian Hopkins
    Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK.
  • Bilal A Mateen
    Alan Turing Institute, Kings Cross, London, UK.
  • Ewan R Pearson
    Division of Population Health and Genomics, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, United Kingdom.
  • Andrew T Hattersley
    Institute of Biomedical and Clinical Science, College of Medicine and Health, University of Exeter, Exeter, United Kingdom.
  • Trevelyan J McKinley
    Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK.
  • Beverley M Shields
    Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK.
  • John M Dennis
    Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK.